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Abstract:	the	Blood-Brain	Barrier	(BBB)	is	a	highly	specialised	interface	separating	the	Central	
Nervous	System	(CNS)	from	circulating	blood.	Dysregulation	of	the	BBB	is	a	key	early	event	in	
pathological	conditions	such	as	inflammation,	in	which	the	entry	of	activated	leukocytes	into	the	
CNS	is	facilitated	by	BBB	breakdown.	The	metzincin	family	of	metalloproteinases	(MPs)	is	one	of	the	
major	contributors	to	BBB	permeability	as	they	cleave	endothelial	cell-cell	contacts	and	underlying	
basal	lamina	components.	However,	the	mechanisms	by	which	MPs	regulate	BBB	integrity	has	not	
yet	been	fully	elucidated.	The	aim	of	this	review	is	to	provide	an	overview	of	pathways	by	which	MPs	
could	regulate	the	BBB	in	the	context	of	neuroinflammation.			
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Development	of	the	BBB	
	
The	Blood-Brain	Barrier	(BBB)	is	a	tightly	regulated	interface	between	the	Central	Nervous	System	
(CNS)	and	the	circulating	blood	that	ensures	a	highly	selective	paracellular	and	transcellular	
exchange	of	molecules	between	the	two	compartments.	Structurally,	the	BBB	is	formed	by	highly	
specialised	capillary	endothelial	cells	(ECs)	discontinuously	wrapped	on	their	luminal	side	by	a	
cellular	layer	of	pericytes.	Together,	ECs	and	pericytes	synthesise	a	basement	membrane	
(comprising	extracellular	matrix	components	including	collagen	IV,	laminin	and	heparan	sulphate	
proteoglycan)	that	provide	structural	support	and	contribute	to	barrier	formation.	Astrocyte	foot	
processes	externally	cover	this	basement	membrane	acting	as	intermediates	between	the	blood	
vessels	and	the	CNS	and	promoting	BBB	stability	through	the	secretion	of	trophic	factors	(see	Fig.	1	
for	a	depiction	of	the	basic	features	of	the	neurovascular	unit)	(Park	et	al.	2003;	Seo	et	al.,	2012).	
The	perivascular	space,	previously	thought	to	be	absent	from	capillaries,	may	well	be	found	
throughout	the	vasculature	(for	review	and	discussion	see	Abbott	et	al.,	2018		and	papers	therein).		
Accumulation	of	immune	cells	within	the	perivascular	space	does	not	necessarily	trigger	full	
neuroinflammation,	as	the	glia	limitans	(formed	by	a	parenchymal	basement	membrane	and	the	
astrocyte	foot	process)	forms	a	second	barrier	that	keeps	the	immune	cells	from	entering	the	CNS	
(reviewed	in	Engelhardt	and	Ransohoff,	2012;	Engelhardt	et	al.,	2016;	Iadecola	2017).		
Cell-cell	interactions	between	neighbouring	ECs	result	in	a	polarized	phenotype	and	very	limited	
transcellular	diffusion,	resulting	in	the	BBB’s	limited	permeability.	Tight	(TJ)	and	adherens	(AJ)	
junctions	link	adjacent	ECs	together	(Kniesel	and	Wolburg,	2000).	TJs	comprise	transmembrane	
proteins	such	as	occludins,	junctional	adhesion	molecules	(JAMs)	and	claudins	which	are	anchored	to	
actin	filaments	via	adaptor	proteins	including	cingulin,	zona	occludens	proteins	(Z0-1,	-2	and	-3)	and	
Ca2+-dependent	serine	protein	kinase	(CASK).	Endothelial	AJs	link	to	the	cytoskeleton	through	
transmembrane	proteins	including	vascular-endothelial	(VE)-cadherin	and	catenins	(α,	β	and	p120)	
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(Fig.	1)	(Dejana	et	al.,	2000;	Kniesel	and	Wolburg,	2000;	Alvarez	et	al.,	2011a).	For	a	detailed	review	
of	endothelial	tight	junctions,	see	Stamatovic	et	al.	(Stamatovic,	et	al,	2016).	
The	development	of	the	BBB	is	a	tightly	regulated	process.	In	the	developing	brain,	neural	progenitor	
cells	secrete	Vascular	Endothelial	Growth	Factor	(VEGF),	which	guides	embryonic	EC	migration	into	
the	developing	brain	(Raab	et	al.,	2004).		Sprouting,	angiogenesis	and	BBB	maturation	are	promoted	
by	Wnt	secreted	by	neural	progenitor	cells,	which	induces	transcription	of	genes	implicated	in	BBB	
maintenance,	such	as	TJ	molecules	(Liebner	et	al.,	2008).	ECs	from	emerging	vessels	release	Platelet	
Derived	Growth	Factor-b	(PDGF-b),	promoting	pericyte	recruitment	to	the	vessel	surface	(Hellström	
et	al,	1999).	Transforming	Growth	Factor-β	(TGF-β)-mediated	cross-talk	between	ECs	and	
surrounding	pericytes	promotes	VE-cadherin	upregulation	in	ECs	(increasing	pericyte	adhesion)	and	
pericyte	deposition	of	ECM	components	(Hill	et	al.,	2014).	Once	vessels	are	formed,	neighbouring	
astrocytes	support	BBB	maturation	through	the	secretion	of	Sonic	Hedgehog	(Shh),	a	trophic	factor	
responsible	for	increased	TJ	protein	expression	in	ECs	(Alvarez	et	al.,	2011b).	
	
BBB	disruption	is	a	pathological	event	
	
BBB	dysfunction	is	widely	implicated	in	the	context	of	brain	injury	and	disease.	Cytotoxic	edema	
through	BBB	disruption	is	a	key	pathological	event	in	a	wide	variety	of	syndromes	such	as	ischemic	
stroke	(Page	et	al.,	2016),	meningitis	(Sellner	and	Leib,	2006)	or	ketoacidosis	(Hoffman	et	al.,	2009).	
BBB	disruption	also	facilitates	the	entry	of	activated	immune	cells	into	the	CNS	and	is	likely	to	be	an	
early	event	in	the	development	of	Multiple	Sclerosis	lesions	(Abbott	et	al.,	2010;	Larochelle	et	al.,	
2011).	In	meningitis,	BBB	disruption,	is	probably	required	for	the	pathogenic	invasion	of	the	CNS	
(Wang	et	al.,	2016).		
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Molecular	and/or	environmental	factors	can	enhance	the	ability	of	circulating	activated	T	cells	to	
cross	the	BBB	and	enter	the	CNS.	Adhesion	molecules	of	the	selectin	family	(such	as	P-selectin	
glycoprotein-1)	expressed	by	the	circulating	activated	leukocytes	interact	with	their	respective	
ligands	up-regulated	on	ECs	(Man	et	al.,	2007;	Engelhardt	et	al.,	2016;	Wang	et	al.,	2016).		Close	
interaction	with	ECs	allows	circulating	leukocytes	to	detect	chemokines	and	cytokines	(released	by	
the	damaged	tissue)	and	leukocyte	tethering	via	the	activation	of	integrins.	The	increased	affinity	
between	the	immune	cell	and	the	endothelium	strengthens	leukocyte	adhesion	to	the	vascular	wall,	
leading	to	a	crawling	process	mainly	mediated	by	alpha	L/M	beta	2	and	alpha	4	beta	1	integrins	and	
their	respective	endothelial	partners	Intercellular	Adhesion	Molecules	(ICAMs)	and	Vascular	Cell	
Adhesion	Molecules	(VCAMs)	(Man	et	al.,	2007;	Engelhard	et	al.,	2016;	Wang	et	al.,	2016).	During	
this	stage,	crawling	immune	cells	scan	the	endothelial	surface	looking	for	a	permissive	site	for	
extravasation	(or	diapedesis),	where	protrusions	from	the	endothelial	plasma	membrane	will	
surround	the	adherent	leukocyte	helping	it	to	migrate	across	the	BBB.	This	extravasation	can	take	
place	through	two	different	routes:	paracellular	diapedesis	and	transcellular	diapedesis.	In	
paracellular	diapedesis	the	activated	leukocyte	migrates	into	the	CNS	by	disrupting	the	endothelial	
junctions	between	adjacent	ECs,	enabling	transmigration	(Man	et	al.,	2007;	Engelhardt	and	
Ransohoff,	2012;	Wang	et	al.,	2016).	Transcellular	diapedesis	occurs	less	frequently	and	is	
characterised	by	clustering	of	ICAM1	(Millan	et	al.,	2006;	reviewed	in	Engelhardt	et	al.,	2016).		In	
conditions	such	as	MS,	once	circulating	autoreactive	T	cells	have	entered	the	CNS,	they	secrete	
proinflammatory	cytokines	such	as	interferon-γ	(INF-γ)	and	tumour	necrosis	factor-α	(TNF-α)	
(Engelhardt,	2006;	Man	et	al.,	2007;	Engelhardt	and	Ransohoff,	2012).	These	cytokines	can	then	
activate	antigen-presenting	cells	(APCs)	and	further	promote	the	migration	of	T	cells	across	the	BBB	
by	increasing	the	expression	of	adhesion	molecules	in	both	circulating	leukocytes	and	ECs.	For	
further	details	of	extravasation	mechanisms	see	reviews	by	Vestweber		and	Engelhardt	and	
colleagues	(Vestweber,	2015;	Engelhardt	et	al.,	2016)	and	for	review	of	immunopathology	of	MS	
development	and	T	cell	subsets	involved	see	Garg	and	Smith	(Garg	and	Smith,	2015)).	Thus,	
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cytokines	play	a	crucial	role	initiating	and	promoting	the	entry	of	pro-inflammatory	cells	into	the	
CNS.	
Many	studies	have	reported	the	role	of	cytokines	in	BBB	disruption	in	neuroinflammatory	disorders.	
Release	of	pro-inflammatory	mediators	is	an	early	event	in	MS	leading	to	BBB	disruption	(Minagar	
and	Alexander,	2003;	Abbott	et	al.,	2010;	Larochelle	et	al.,	2011).	Elevated	levels	of	circulating	TNFα,	
IL-17A	and	decreased	levels	of	circulating	IL-10	were	reported	in	Multiple	Sclerosis	patients	(Trenova	
et	al.,	2018).	Although	the	exact	mechanisms	by	which	cytokines	trigger	BBB	disruption	are	
incompletely	understood,	reduced	levels	of	TJ	proteins	(such	as	Z0-1,	claudin-5	and	occludin)	have	
been	reported	in	several	model	systems	(Forster	et	al.,	2008;	Aslam	et	al.,	2012;	Cohen	et	al.,	2013;	
Labus	et	al.,	2014).	Anti-inflammatory	cytokines	such	as	IL-4	and	IL-10	can	ameliorate	brain	lesions	
and	cellular	infiltration	in	a	murine	model	of	Multiple	Sclerosis	(Hosseini	et	al.,	2017),	and	
termination	of	inflammation	together	with	repair	mechanisms	can	be	promoted	by	microglial	
secretion	of	IL-10,	transforming	growth	factor	β		(TGFβ)	and	insulin-like	growth	factor	1	(IGF1)	
(Amantea	et	al.,	2015).	For	an	overview	of	factors	controlling	BBB	permeability,	see	Almutairi	et	al.	
(Almutair	et	al.,	2016).	
	
Metzincins	play	a	key	role	during	BBB	disruption	
	
Metzincins,	comprising	Matrix	Metalloproteinases	(MMPs),	A	Disintegrin	And	Metalloproteinases	
(ADAMs)	and	A	Disintegrin	And	Metalloproteinase	with	Thrombospondin	motifs	(ADAMTS),	are	a	
family	of	zinc	containing	proteinases	widely	implicated	in	the	biology	of	the	nervous	system	
(reviewed	in	(Rivera	et	al.,	2010)).	
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MMPs:	
	
MMPs	are	synthesized	as	inactive	enzyme	precursors	containing	a	signal	peptide,	directing	secretion	
or	localisation	to	the	plasma	membrane.	MMP	catalytic	activities	have		mainly	been	studied	in	the	
extracellular	environment	and	at	the	cell	surface	(Fanjul-Fernandez	et	al.,	2010).	MMP	activity,	(as	
well	as	activation	in	some	cases),	is	inhibited	by	the	four	Tissue	Inhibitors	of	Metalloproteinases	
(TIMPs)	(Larochelle	et	al.,	2011).	In	humans,	23	different	MMPs	have	been	classified	according	to	
differences	in	their	domain	structure	and	original	ECM	substrate	specificity	(Fig.	2)	(Yong,	2005;	
Rivera	et	al.,	2010).	The	pioneering	proteomic	approaches	taken	by	Chris	Overall	and	several	other	
groups	over	the	last	20	years	have	revealed	that	MMPs	can	cleave	many	novel	substrates,	including	
cell-cell	junction	components,	chemokines,	cytokines	and	their	receptors	as	well	as	growth	factors	
(reviewed	in	Schlage	and	auf	dem	Keller,	2015).		These	findings	have	informed	much	of	the	recent	
research	regarding	MMPs	in	BBB	breakdown.	In	addition	proteomic	approaches	reveal	that		MMP	
action	intracellularly	is	of	emerging	importance	(reviewed	in	Jobin	2017),	but	will	not	be	further	
considered	here.	MMPs	are	tightly	regulated	at	three	main	levels:	at	the	transcriptional	level	(eg	
cytokine-induced	transcription),	by	proteolytic	activation	of	their	initial	inactive	form	exposing	their	
active	catalytic	domain	and	through	inhibition	by	TIMPs.	Additionally,	MMP	activity	can	also	be	
controlled	by	post-translational	modifications,	substrate	availability	and	cellular	localization	
(reviewed	in	Yong,	2005).		
A	major	consequence	of	neuroinflammation	is	the	up-regulation	of	MMPs	(Rempe	et	al.,	2016).	
Components	of	endothelial	cell	TJs	and	AJs	as	well	as	the	extracellular	matrix	surrounding	ECs	and	
pericytes,	can	be	cleaved	by	members	of	this	large	family	of	proteinases	(Fanjul-Fernandez	et	al.,	
2010;	Eisenach	et	al.,	2012;	Liu	et	al.,	2012).	Additionally,	several	studies	using	broad	spectrum	
metalloproteinase	inhibitors	points	at	metzincins	as	main	mediators	of	BBB	pathological	disruption.	
Administration	of	a	broad	spectrum	(M)MPs	inhibitor	in	a	rat	model	of	meningitis	(Paul	et	al.,	1998)	
or	stroke	(Pfefferkorn	and	Rosenberg,	2003),	and	a	murine	model	of	multiple	sclerosis	(Gijbels	et	al.,	
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1994)	resulted	in	suppression	of	induced	BBB	permeability.	Interestingly,	the	ability	of	LPS	to	trigger	
BBB	damage	and	the	ability	of	the	tested	broad	spectrum	(M)MPs	inhibitors	to	block	LPS-induced	
BBB	disruption	was	mouse	strain-dependent,	suggesting	that	genetic	background	could	be	playing	
an	important	role	(Rosenberg	et	al.,	2007).		
MMP	induction	is	associated	with	inflammation	and	brain	injury:	early	studies	revealed	high	levels	of	
MMP9	together		with	a	reduction	in	inhibitor	levels	(TIMP1)	in	serum	from	Multiple	Sclerosis	(MS)	
patients	(an	autoimmune	disorder	in	which	early	BBB	breakdown	is	likely	to	precede	invasion	of	
autoreactive		immune	cells	into	the	CNS)	(Lee	et	al.,	1999;	Waubant	et	al.,	1999).	During	ischemia	
MMP3	expression	levels	can	be	elevated	triggering	loss	of	BBB	integrity	(Rosenberg	et	al.,	2001;	
Gurney	et	al.,	2006).	Observed	dysregulation	of	MMP	levels	may	initiate	BBB	damage	since	several	
members	of	this	family	are	capable	of	cleaving	TJ	and	basement	membrane	elements	(summarised	
in	Table	1).	Claudins,	occludins	and	Z0-1	proteins	can	be	directly	cleaved	by	MMP1	(Wu	et	al.,	2015),	
-2	(Yang	et	al.,	2007),	-9	(Yang	et	al.,	2007;	Bauer	et	al.,	2010)	and	-13	(Lu	et	al.,	2009)	amongst	
others.	Membrane	anchored	MMPs	also	activate	other	MMPs,	as	well	as	degrading	basement	
membrane	elements	such	as	collagen	IV	and	laminin	(Itoh,	2015).	In	murine	model,	MMP2	and	-9	
can	cleave	dystroglican	(a	transmembrane	receptor	responsible	for	astrocyte	foot	processes	
anchorage	to	the	basement	membrane)	promoting	leukocyte	infiltration,	discussed	in	more	detail	
later	(Agrawal	et	al.,	2006).	Additionally,	pro-inflammatory	cytokines	can	also	be	proteolytically	
activated	by	mentzincines,	suggesting	the	existence	of	a	feedback	loop	mechanism	between	(M)MPs	
and	pro-inflammatory	agents:	TNFα	can	be	cleaved	and	activated	by	ADAM17	as	well	as	by	MMPs7,	-
12,	-14	and	-17;	IL-1β	can	be	proteolytically	activated	by	MMPs2,	-3	and	-9;	and	MMP9	can	mediate	
interferon-β	inactivation	(reviewed	in	(Rodriguez	et	al.,	2010).	Interestingly,	ADAMs	8	and	-17	can	
shed	TNFα	receptor	(TNFR),	releasing	soluble	form	of	TNFR	which	can	sequester	extracellular	TNFα	
ameliorating	inflammation	(Reddy	et	al.,	2000;	Bartsch	et	al.,	2010).	IL-1R	and	IL-6R	can	be	shed	by	
ADAM10	and/or	-17		(Reddy	et	al.,	2000;	Schumacher	et	al.,	2015),	releasing	a	soluble	fraction	
capable	of	stabilising	IL-1	or	IL-6	and	exacerbate	the	inflammatory	response.	Metzincins	can	also	
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target	a	wide	range	of	chemokines,	regulating	the	recruitment	of	activated	immune	cells:	MMPs	8	
and	9	can	cleave	IL-8	enhancing	their	chemotactic	activity	(Van	den	Steen		et	al.,	2000;	Van	Den	
Steen	et	al.,	2003;	Tester	et	al.,	2007).	Studies	in	MMP8	null	mice	showed	an	impaired	recruitment	
of	activated	immune	cells	following	LPS	stimulation,	corroborating	the	in	vitro	data	(Tester	et	al.,	
2007).		MMP12	participates	in	the	termination	of	inflammation	through	the	cleavage	and	
inactivation	of	most	members	of	the	CXCL	chemokine	family	(Dean	et	al.,	2008).		Thus,	there	is	
complex	duality	underlying	mentzincines	roles	in	the	processing	of	chemokines	(reviewed	in	
Rodriguez	et	al.,	2010).	Metzincins	cannot	only	modulate	the	infiltration	of	activated	immune	cells	
through	the	direct	opening	of	the	BBB,	but	also	through	their	recruitment	and	activation	via	
chemokine	processing.	For	further	discussion	of	MMPs	in	brain	disease	see	Rempe	et	al.	(2016)	
(Table	1).	
ADAMs	
	
The	ADAM	family	shares	great	structural	similarities	with	MMPs	(Fig.	2),	and	has	also	been	
implicated	in	BBB	disruption	(reviewed	in	Reiss	and	Saftig,	2009).	ADAMs	have	major	roles	in	
shedding	molecules	from	the	cell	surface	(for	a	new	comprehensive	sheddome	database	see	Tien	et	
al.,	2017).	Within	the	ADAM	family,	ADAM10	and	ADAM17	are	the	principal	shedding	enzymes	and	
during	inflammatory	conditions	may	promote	BBB	leakage	through	the	shedding	of	adhesion	
molecules	expressed	by	ECs	(reviewed	in	Dreymueller	et	al.,	2012a).	In	addition,	the	expression	of	
ADAM17	has	been	found	to	be	up-regulated	in	active	lesions	during	MS	(Plumb	et	al.,	2006).	Recent	
evidence	indicates	that	Natalizumab	(an	anti-alpha	4	integrin	antibody)	treatment	in	patients	with	
multiple	sclerosis,	which	blocks	leukocyte	adhesion	to	VCAM-1	on	inflamed	endothelial	cells	also	
results	in	reduction	in	circulating	soluble	Vascular	Cell	Adhesion	Molecule	1	(sVCAM-1)	levels	
(Petersen	et	al.,	2016).	VCAM-1	shedding	is	ADAM17-dependent	(Garton	et	al.,	2003;	Singh	et	al.,	
2005).	Whether	Natalizumab	effects	on	VCAM-1	levels	are	ADAM17-mediated	remains	to	be	
studied,	although	it	could	be	speculated	that	Natalizumab	blockade	of	activated	immune	cell	
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recruitment	could	lead	to	a	local	decrease	in	secreted	cytokines,	leading	to	a	downregulation	in	
ADAM17	activation	and	a	possible	reduction	in	VCAM-1	shedding.		
ADAMTS		
	
A	Disintegrin	and	Metalloproteinase	with	Thrombospondin	motifs	(ADAMTS)	proteinases	are	
secreted	extracellular	enzymes	with	a	characteristic	thrombospondin	type	1	sequence	repeat	(TSR)	
motif	that	share	the	same	catalytic	domain	as	MMPs	and	ADAMs	(Figure	2)	(Kelwick	et	al.,	2015).	
Several	members	of	this	family	have	been	implicated	in	BBB	disruption:	genetic	linkage	studies	in	
Multiple	Sclerosis	patients	have	associated	ADAMTS14	(a	procollagen	aminopropeptidase)	with	this	
disease	(Goertsches	et	al.,	2005)	whereas	studies	in	an	ischemic	murine	model	have	reported	that	
ADAMTS13	blocks	tissue	Plasminogen-induced	BBB	disruption	after	cerebral	stroke	(Wang	et	al.,	
2013)	(Table	1).	
Despite	recent	advances	in	our	understanding	of	metalloproteinases,	the	precise	underlying	
mechanisms	by	which	metzincins	regulate	BBB	stability	remain	uncertain.	Many	pathways	can	
regulate	BBB	integrity	during	adulthood.	In	this	review	we	aim	to	highlight	signalling	pathways	which	
are	already	implicated	in	metzincin-mediated	regulation	of	BBB	integrity	as	well	as	those	which	are	
deserving	of	further	study.						
	
Pathways	implicated	in	metzincin	regulation	of	BBB	integrity		
	
Several	pathways	have	been	implicated	in	development	of	the	BBB,	some	of	which	have	also	been	
explored	in	the	context	of	disease.	For	each	pathway,	we	consider	the	pathway’s	role	in	
development	and/or	maintenance	of	the	BBB	and	indicate	where	metzincins	have	established	or	
emerging	roles.	We	also	make	reference	to	other	systems	where	metzincin	interaction	is	of	
importance	and	which	may	provide	useful	pointers	for	future	BBB	research.			
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Hedgehog	Pathway	
	 	
The	importance	of	astrocyte-secreted	Shh	in	BBB	maintenance	has	emerged	in	recent	years.	
Compelling	evidence	for	the	role	of	hedgehog	signalling	in	BBB	maintenance	in	adult	mice	has	been	
provided	by	Alvarez	and	colleagues	(Alvarez	et	al.,	2011b).	In	the	hedgehog	pathway	the	absence	of	
Shh,	the	cell	surface	receptor	patched	(Ptch)	functions	as	a	constitutive	inhibitor	of	Smoothened	
(Smo).	Upon	Shh-Ptch	binding,	Smo	initiates	the	Shh	signalling	cascade,	resulting	in	the	activation	of	
the	Gli	family	of	transcription	factors	(Gli1,	Gli2	and	Gli3)	(Benson	et	al.,	2004;	Choudhry	et	al.,	
2014).	By	selectively	deleting	Smo	in	mouse	brain	ECs,	a	decrease	in	junctional	proteins	(claudins	-3	
and	-5,	occludin	and	Z0-1)	accompanied	by	a	fragmented	basement	membrane	and	higher	BBB	
permeability	in	vivo	was	observed	(Alvarez,	et	al.,	2011b).	Studies	in	ECs	show	that	Shh	promotes	
neovascularization	through	upregulation	of	pro-angiogenic	factors	(including	VEGF)	as	well	as	MMP2	
and	9	(Renault	et	al.,	2010;	Yi	et	al.,	2016).	Interestingly,	Renault	et	al.	suggest	that	a	non-classical,	
alternative	pathway	involving	Rho	could	mediate	Shh-induced	angiogenesis	and	MMP9	upregulation	
in	Human	Umbilical	Vein	Endothelial	Cells	(HUVECs)	(Renault	et	al.,	2010).	In	a	disease-mimicking	
context,	cytokine	IL1β	suppresses	Shh	expression	in	murine	astrocytes	whilst	elevating	levels	of	a	
number	of	chemokines	(Wang	et	al.,	2014).		Conditioned	media	from	untreated	astrocytes	was,	as	
expected,	important	in	promoting	barrier	formation	in	endothelial	cells	whilst	medium	from	
cytokine-treated	astrocytes	abrogated	this	effect	(Wang	et	al.,	2014).	Very	recently,	conditioned	
medium	from	mycobacterium	tuberculosis	(MTb)-infected	monocytes	was	shown	to	up-regulate	
MMP9	expression	in	astrocytes	and,	as	well	as	cleaving	type	IV	collagen,	induced	MMP9	had	an	
additional	role	in	preventing	Shh	delivery	from	astrocytes	to	endothelial	cells	(Brilha	et	al.,	2017).	
Protein	levels	of	claudin-5,	occludin	and	ZO-1	were	all	reduced	but	mechanisms	underpinning	these	
observations	remain	unexplored.	The	fact	that	Shh	can	induce	MMPs	in	endothelial	cells	raises	a	
HI
ST
OL
OG
Y 
AN
D 
HI
ST
OP
AT
HO
LO
GY
 
(no
n-e
dit
ed
 m
an
us
cri
pt)
12	
	
potential	tension	between	BBB	formation	and	breakdown	mediated	by	this	pathway,	which	is	
worthy	of	further	investigation.		
	
Notch	Pathway	
	 	
The	Notch	pathway	has	been	implicated	in	vascular	barrier	integrity	(for	review	see	(Cai	et	al.,	2016))	
but	the	underlying	metalloproteinase	involvement	in	the	context	of	the	BBB	remains	unclear.	Upon	
binding	to	their	ligands,	Jagged	and	Delta-like	(Dll),	the	Notch	family	of	transmembrane	receptors	
(Notch1	to	4	in	mammals)	are	generally	cleaved	by	ADAM10,	enabling	γ-secretase-mediated	release	
of	the	Notch	intracellular	domain	(NICD),	which	translocate	to	the	nucleus.	Here	the	NCID	associates	
with	CSL	and	Mastermind-like-1	(MAMIL)	to	regulate	gene	transcription	(reviewed	in	(Siebel	and	
Lendahl,	2017;	Wetzel	et	al.,	2017)).	Interestingly,	Notch	shedding	can	be	also	be	triggered	in	a	
ligand-independent	manner,	involving	endosomal	localisation/association	(reviewed	in	(Palmer	and	
Deng,	2015;	La	Foya	2016)).		Notch	interaction	with	the	wnt	signalling	pathway	may	impact	on	
vascular	barrier	integrity	through	NCID/β-catenin	regulation	of	gene	expression	or	through	triggering	
of	β-catenin	degradation	(reviewed	in	La	Foya	2016).	
Early	studies	have	showed	roles	for	ADAM10	(Pabois	et	al.,	2015;	Zhuang	et	al.,	2015)	and	ADAM17	
(Broux	et	al.,	2012)	in	the	extracellular	cleavage	of	Notch.	Murine	deletion	studies	demonstrated	
that	ADAM10	plays	a	role	in	blood	vessel	development	in	several	vascular	beds,	such	as	liver,	bone	
and	retina	(Glomski	et	al.,	2011).	However,	histopathological	observations	revealed	that	mice	with	
an	endothelial-specific	ADAM10	do	not	develop	major	phenotypic	defects	in	the	brain	(Alabi	et	al.,	
2016).	This	comprehensive	study	revealed	that	endothelial-specific	deletion	of	Notch1	and	Notch4	
phenocopies	the	ADAM10-deleted	mice.	ADAM10/17	double	knockout	mice	did	not	show	any	
additional	defects,	demonstrating	that	ADAM10	is	the	key	proteinase	in	these	interactions.	Further	
studies	will	determine	whether	ADAMs	10	or	17	are	implicated	in	Notch	signalling	in	relation	to	
functional	maintenance	of	the	BBB	in	adult	mice	and	in	disease.		The	same	study	revealed	that	Notch	
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1	and	Notch	4	have	partially	overlapping	roles	in	vascular	barriers	(Alabi	et	al.,	2016).	Additionally,	
ADAM10	and	Notch	can	respond	to	inflammatory	stimuli	in	other	vascular	pathologies:	in	an	in	vivo	
model	of	vascular	inflammation	an	increase	in	IL-6	was	mediated	by	ADAM10-dependent	shedding	
of	Notch,	suggesting	that	ADAM10	activation	of	Notch	signalling	could	be	involved	in		inflammation	
and	recruitment	of	activated	immune	cells	(Pabois	et	al.,	2015).		
	
Oxidative	stress	can	synergistically	trigger	a	reduction	in	Notch4	and	Z0-1	protein	levels	in	brain	ECs	
isolated	from	rats	(Manda	et	al.,	2010).	However,	it	remains	to	be	determined	whether	the	
described	loss	in	BBB	stability	is	Notch4-dependent	or	a	broader	consequence	of	oxidative	stress	
exposure.	Notch3	(expressed	by	surrounding	vascular	smooth	muscle	cells	(VSMCs))	plays	a	key	role	
in	BBB	maintenance,	as	Notch3-/-	mice	exhibit	enhanced	BBB	permeability	in	vivo	(assessed	by	
Evans	Blue	and	Horseradish	Peroxidase	extravasation)	(Henshall	et	al.,	2015).	Thus,	members	of	the	
Notch	family	may	exert	different	effects	under	the	same	conditions	depending	on	the	overall	activity	
of	the	Notch	pathway.	Supporting	this	idea,	in	vivo	and	in	vitro	studies	in	human	brain	microvascular	
ECs	(HBMECs)	suggest	a	role	for	Notch1	rather	than	Notch3	(whose	expression	is	specific	to	VSMCs)	
to	be	a	key	mediator	in	cocaine-induced	BBB	breakdown	(Yao	et	al.,	2011).	Although	EC	to	EC	Notch	
signalling	has	been	previously	reported	to	be	essential	during	angiogenesis	and	vascular	homeostasis	
(Noseda	et	al.,	2004)	more	recent	studies	suggest	the	existence	of	a	complex	Notch	cross-talk	
between	all	the	components	of	the	NVU.	A	thorough	characterization	of	Notch	receptor	and	ligand	
expression	among	the	components	of	the	NVU	shows	a	heterogeneous	and	complex	distribution	of	
these	components:	Notch	1	and	4	are	expressed	in	ECs	together	with	the	ligands	Jagged2	and	Dll4;	
Notch	2	and	3	are	present	in	astrocytes;		Jagged	1	is	located	in	pericytes	and	neurons	express	Dll1	
(Yamamizu	et	al.,	2017).	Supporting	this	idea,	neuron-derived	Dll	was	reported	to	be	needed	for	the	
complete	differentiation	of	brain	ECs	in	a	complex	co-culture	in	vitro	model	of	the	BBB	(Yamamizu	et	
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al.,	2017).	Studies	in	mouse	retina	showed	that	Notch3	is	required	for	pericyte	attachment	to	ECs	in	
an	N-cadherin	dependent	manner	(Liu	et	al.,	2010).		
	
One	of	the	many	consequences	of	Notch1	activation	is	the	inhibition	of	Phosphatase	And	Tensin	
Homolog	(PTEN),	downstream	of	Notch,	and	the	consequent	activation	of	PI3K/p-Akt	pathway	(El-
Habr	et	al.,	2014;	Song	et	al.,	2015).	The	role	played	by	the	Serine/Threonine	kinase	Akts	in	BBB	
integrity	remains	to	be	fully	clarified.	Studies	with	Akt1-/-/Akt2-/-	double	KO	mice	showed	no	altered	
EC	survival,	but	a	gradual	loss	of	VSMCs	due	to	reduced	Jagged1/Notch	signalling	(Kerr	et	al.,	2016).		
	
Conflicting	with	the	previously	discussed	studies	in	Notch3-/-	mice	(Henshall	et	al.,	2015),	Akt1-/-
/Akt2-/-	double	KO	mice	exhibit	an	intact	BBB	(Kerr	et	al.,	2016).	However,	the	assessment	of	BBB	
properties	in	this	study	was	performed	through	NaF	permeability,	a	very	low	molecular	weight	
molecule	broadly	used	to	measure	basement	membrane	permeability	to	water	and	other	small	
solutes	rather	than	large	molecules	such	as	dextran.	A	mathematical	prediction	of	BBB	functions	
suggests	that	even	when	TJs	are	compromised,	the	basement	membrane	and	astrocyte	foot	
processes	could	theoretically	maintain	a	low	permeability	to	water	and	other	small	solutes	(Li	et	al.,	
2010).	Hence,	it	is	possible	that	a	functional	basement	membrane	in	the	Akt1-/-	and	Akt2-/-	double	
KO	could	mask	TJ	dysfunction	when	tested	with	NaF,	explaining	the	apparently	contradictory	results.		
Despite	the	uncertain	role	of	Notch	signalling	in	BBB	stability,	a	role	for	secreted	MMP9	and	MMP2	
in	shedding	extracellular	Notch1	(consequently	enhancing	Notch1	signalling)	has	been	suggested	in	a	
murine	model	of	MS	(experimental	autoimmune	encephalomyelitis,	EAE).	Song	and	colleagues	
showed	an	up-regulation	of	Notch1-specific	transcription	factors	in	MMP2-	and	MMP9-treated	
astrocytes	(Song	et	al.,	2015).	Additionally,	in	vitro	experiments	showed	reduced	T	cell	
transmigration	in	the	presence	of	primary	Notch1-/-	astrocytes	exposed	to	a	pro-inflammatory	
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environment.	Reduced	astrocytic	chemotactic	activity	and	chemokine	secretion	could	not	be	
restored	by	addition	of	activated	MMP2	or	MMP9	(Song	et	al.,	2015).	The	key	roles	of	MMP2	and	
MMP9	as	mediators	of	leukocyte	infiltration	into	the	CNS	have	been	shown	in	MMP2-/-/MMP9-/-	
double	knock-out	mice,	but	levels	of	Notch	proteolytic	activation	were	not	assessed	in	this	context.	
MMP14	(or	MT-MMP-1)	can	also	trigger	Notch	proteolytic	activation	but	its	impact	in	the	context	of	
the	BBB	remains	to	be	clarified	(Ma	et	al.,	2014)	(Fig.	3).		
Pathways	to	cytoskeletal	reorganization	
			
TNFα	stimulation	of	brain	microvascular	ECs	results	in	the	formation	of	actin	stress	fibres,	loss	of	Z0-
1	immunostaining	and	increased	barrier	permeability	at	early	time-points,	which	can	be	reversed	by	
MMP9	inhibition	(Wiggins-Dohlvik	et	al.,	2014).	As	previously	mentioned,	Z0	proteins	act	as	a	link	
between	transmembrane	components	of	the	TJ	(occludins	and	claudins)	and	the	actin	cytoskeleton	
(Fanning	et	al.,	1998;	Itoh	et	al.,	1999),	similar	to	the	role	of	catenins	during	AJ	formation	(Yap	et	al.,	
1997).	Thus,	Z0	proteins	work	as	adaptors	between	the	dynamic	cytoskeleton	and	the	stable	TJ,	
providing	ECs	with	a	barrier	which	can	adjust	to	different	cellular	requirements.	Under	certain	
environmental	conditions,	actin	filaments	can	change	their	usual	conformation	(distributed	across	
the	ECs	as	short	filaments	and	monomers)	and	polymerize	into	large	structures	known	as	stress	
fibres	(Burridge	and	Wittchen,	2013).	In	vitro	studies	using	isolated	mouse	brain	capillaries	and	
HBMECs	have	shown	that	stress	fibres	can	increase	cytoskeletal	tension	leading	to	an	impaired	TJ	
formation	through	a	RhoA/Rho	kinase	(ROCK)-mediated	mechanism	(McKenzie	and	Ridley,	2007;	Shi	
et	al.,	2016).		This	actin-mediated	disassembly	of	TJs	could	result	in	the	opening	cell-cell	contacts,	
exposing	other	junctional	proteins	and	ECM	components	to	the	degradation	by	surrounding	(M)MPs.			
	
Actin	contractility	is	induced	by	the	phosphorylation	of	myosin	light	chain	(MLC),	which	is	in	turn	
activated	by	the	ROCK/myosin-light	chain	kinase	(MLCK)	pathway	(Hathaway	et	al.,	1981).	This	
HI
ST
OL
OG
Y 
AN
D 
HI
ST
OP
AT
HO
LO
GY
 
(no
n-e
dit
ed
 m
an
us
cri
pt)
16	
	
impairment	of	TJ	formation	leads	to	an	increased	permeability	to	small	molecules	and	activated	
immune	cells	in	a	well-established	in	vitro	model	of	the	BBB	(Shi	et	al.,	2016).		
Studies	in	immortalised	human	brain	microvascular	ECs	(hCMEC/D3)	report	an	actin-mediated	
nuclear	translocation	mechanism	for	Z0-1	after	activation	of	the	ROCK/MLCK	pathway	that	will	result	
in	Z0-1	internalization	and	TJ	impairment.	This	research	also	demonstrated	that	Rho	activation	
triggered	cAMP	Response	Element	Binding	Protein	(CREB)	phosphorylation,	which	in	turn	could	
enhance	MLC	activation	(Zhong	et	al.,	2012).	CREB	is	a	transcription	factor	that	can	recognize	and	
bind	to	a	CREB	responsive	element	(CRE)	present	in	the	promoter	region	of	many	cAMP-responsive	
genes	(Johannessen	et	al.,	2004)	including	ZO-1	(Chen	et	al.,	2008;	Zhong	et	al.,	2012)	.		Akt	can	
phosphorylate	CREB	on	Ser133	leading	to	its	activation(Du	and	Montminy,	1998).	Thus,	it	could	be	
proposed	that	Akt-mediated	phosphorylation	of	CREB	can	enhance	DNA	binding	activities	leading	to	
an	increase	in	Z0-1	transcription,	which	would	enhance	barrier	properties	in	the	context	of	the	BBB	
(Fig.	3).		
Akt	is	frequently	activated	down-stream	of	BBB	disrupting	agents	including	inflammatory	cytokines,	
and	attention	has	turned	more	recently	to	its	role	in	localisation	of	TJ	proteins:	in	the	bEND.3	cell	
line	cytokine	treatment	results	in	early	loss	of	paracellular	claudin-5	localisation	via	the	PI3K/Akt	
pathway	(Camire	et	al.,	2014;	Machida	et	al.,	2017).	In	a	co-culture	model	of	rat	pericytes	and	ECs,	
thrombin	can	induce	pericyte	release	of	MMP9	through	PAR1/Akt	activation	(Machida	et	al.,	2017).		
It	is	also	possible	that	Akt	could	be	mediating	TJ	formation	through	direct	phosphorylation	of	Z0-1	
(Furuse	et	al.,	1999).	Whereas	Z0-1	tyrosine	phosphorylation	has	been	correlated	with	both	
increased	and	decreased	barrier	permeability,	depending	on	the	cell	type,	in	epithelial	cells	
serine/threonine	phosphorylation	has	mainly	been	described	to	impair	TJ	function	through	the	
internalization	of	Z0-1	(Harhaj	and	Antonetti,	2004).	Akt	mediated	phosphorylation	can	also	enhance	
Z0-1-dependent	TJ	formation	in	diabetic	mouse	retina	explants	(likely	in	the	vasculature)	(Liu	et	al.,	
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2012).Thus,	studies	of	direct	effects	of	Akt-driven	phosphorylation	of	Z0-1	in	the	context	of	the	BBB	
may	be	warranted.		
	
Overall,	it	seems	that	the	Akt/CREB	pathway	could	mediate	opposing	effects	on	BBB	stability:	
inducing	Z0-1	internalization	and	TJ	disruption	or	directly	promoting	Z0-1	gene	expression.		Thus,	the	
Akt/CREB	pathway	may	be	acting	as	an	intracellular	node	that	enhances	or	impairs	TJ	stability	
depending	on	the	environmental	conditions	(Fig.	3).	Interestingly,	McKenzie	et	al.	(2007)	reported	
that	a	TNFα	effect	on	cytoskeletal	rearrangements,	through	ROCK/MLCK	pathway,	was	enough	to	
cause	TJ	distribution	at	early	time-points	but	insufficient	to	trigger	long-term	effects	on	EC	
permeability.	These	observations	suggest	that	TJ	distribution	and	stability	could	be	responding	to	
internal	mechanisms	depending	on	the	time-points	studied	(McKenzie	and	Ridley,	2007).	
Overall,	regulation	of	Z0-1	cellular	localization	seems	to	play	an	essential	role	in	BBB	stability	by	
affecting	TJ	assembly	directly.	In	addition,	and	as	previously	mentioned,	as	well	as	being	a	substrate	
for	MMP9	(and	other	MPs	potentially),	ZO-1	re-distribution	may	result	in	exposure	of	other	
junctional	proteins,	opening	cell-junctions	to	allow	access	by	(M)MPs	to	basement	membrane	
components,	resulting	in	their	subsequent	cleavage.		
	
NFκβ	pathway	
	
NFκβ	is	a	heterodimeric	transcription	factor	which	has	long	been	established	to	activate	
transcription	of	several	MMPs	(Richmond,	2002).	A	number	of	inflammatory	cytokines	trigger	the	
NFκβ	pathway	resulting	in	loss	of	TJ	integrity,	and	consequent	BBB	disruption	(Chen	et	al.,	2011;	
Aslam	et	al.,	2012;	Coelho-Santos	et	al.,	2015).	NFκβ	can	be	sequestered	in	the	cytoplasm	by	the	
Inhibitor	of	κβ	(Iκβ),	whose	phosphorylation	on	specific	Serine	residues	leads	to	its	ubiquitination	
and	proteasome	degradation,	freeing	NFκβ	to	enter	the	nucleus,	bind	to	its	specific	promoter	
HI
ST
OL
OG
Y 
AN
D 
HI
ST
OP
AT
HO
LO
GY
 
(no
n-e
dit
ed
 m
an
us
cri
pt)
18	
	
elements	and	activate	gene	transcription	(Fig.	3).	Despite	the	fact	that	Iκβ	phosphorylation	is	not	
directly	regulated	by	Akt,	it	has	been	suggested	that	Akt	can	mediate	the	activation	of	the	Iκβ	kinase	
complex	(IKK)	resulting	in	Iκβ	phosphorylation	and	consequent	degradation	(Li	and	Stark,	2002;	Bai	
et	al.,	2009).		In	vitro	studies	in	Human	Umbilical	Vein	ECs	(HUVECs)	suggest	Akt	could	be	a	mediator	
of	NFκβ	nuclear	transduction	in	the	context	of	the	vascular	endothelium,	although	if	Akt’s	effects	on	
NFκβ	cellular	location	are	direct	or	indirect	remains	to	be	determined	(Yu	et	al.,	2014).		
The	NFκβ	family	of	transcription	factors	can	regulate	the	expression	of	a	wide	range	of	genes	
implicated	in	various	cellular	mechanisms,	and	some	are	intimately	involved	in	the	formation	of	TJs:	
in	ECs	NFκβ	directly	represses	claudin-5	expression	by	binding	to	its	promoter	(Aslam	et	al.,	2012)	
and	binding	regions	have	been	identified	in	MMP14	promoter	(Haas	et	al.,	1999).	Studies	in	several	
cell	types	point	to	many	possible	BBB-related	genes	that	could	be	also	regulated	by	NFκβ,	yet	to	be	
studied	in	an	EC-BBB	context.	For	example,	NFκβ	binding	regions	have	been	identified	in	the	
occludin	promoter	(Wachtel	et	al.,	2001;	Kimura	et	al.,	2008);	characterization	of	the	MLCK	human	
promoter	showed	various	NFκβ	responsive	elements	(Graham	et	al.,	2006)	(which	will	lead	to	TJ	
internalization	as	previously	discussed).	NFkβ	activation	also	results	in	the	transcription	of	several	
(M)MPs	(such	as	MMP1,	3,	-9,	-10,	-12	and	-13	(Lee	et	al.,	2007;	Akhtar	et	al.,	2010;	Fanjul-Fernandez	
et	al.,	2010;	Nakayama,	2013;	Yun	et	al.,	2014)	and	some	ADAMTS	proteinases	(Li	et	al.,	2015;	Sun	et	
al.,	2015).	Recent	in	vitro	studies	with	a	human	brain	microvascular	EC	line	(bEnd.3)	has	shown	that	
under	hypoxic	conditions	NFκβ	can	mediate	BBB	disruption	through	enhanced	MMP9	expression	
(Won	et	al.,	2015).		
Of	particular	interest	is	the	already	discussed	role	of	MMP9	in	Notch1	activation,	since	it	raises	the	
possibility	of	a	positive	feedback	loop	between	the	NFκβ	and	Notch	pathways.	MMP9-mediated	
Notch	activation	will	lead	to	PTEN	inhibition	and	the	consequent	Akt	activation,	now	able	to	enhance	
NFκβ	DNA	binding	ability	and	the	transcription	of	those	NFκβ	responsive	genes,	such	as	MMP9	
further	compromising	BBB	integrity	(Fig.	3).		
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Additional	complexity	in	the	NFκβ	pathway	is	provided	by	membrane-type	matrix	
metalloproteinases	(MT-MMPs)	some	of	which	have	a	cytoplasmic	tail	that	can	trigger	signal	
transduction	cascades	(Itoh,	2015).	For	example	in	macrophages,	MMP14	(also	known	as	MT-MMP-
1)	can	induce	the	PI3K/Akt	signalling	cascade	in	a	proteinase-independent	manner	(Ohtake,	2006).	
Studies	in	a	human	breast	cancer	cell	line	confirm	MMP14	activation	of	Akt,	and	also	showed	that	
Akt	inhibition	triggered	a	reduction	in	MMP14	levels	(Eisenach	et	al.,	2010)	supporting	the	previously	
discussed	idea	that	Akt	may	be	mediating	(M)MPs	expression	by	ultimately	modulating	the	activity	
of	particular	transcription	factors	(such	as	NFκβ).	A	number	of	studies	have	explored	the	roles	of	
MMP14	in	endothelial	cell	signalling	(reviewed	in	Ohkawara	et	al.	(Ohkawara	et	al.,	2015))	showing	a	
TNFα-dependent	reduction	in	Akt	phosphorylation	and	an	association	of	cytoplasmic	MMP14	with	
Akt	which	can	modulate	NFKβ	responses	(Findley	et	al.,	2007).	More	recent	studies	show	that	under	
oxidative	stress	(a	well	described	activator	of	NFκβ),	the	presence	of	a	broad	spectrum	(M)MP	
inhibitor	could	reverse	induced	occludin	loss	and	intercellular	gap	formation,	although	barrier	
function	was	not	restored.	These	results	suggest	that	in	addition	to	(M)MPs,	there	is	a	complex	
effect	of	oxidative	stress	in	barrier	permeability	(Lischper	et	al.,	2010).					
	Thus	(M)MPs	may	modulate	signalling	pathways	underlying	BBB	integrity	as	well	as	acting	as	
proteolytic	enzymes	responsible	for	direct	BBB	disruption	but	the	cellular	context/stimulus	is	key.		
	
Adherens	Junctions	in	metzincin-mediated	BBB	integrity		
	
		The	impact	of	metzincins	on	Adherens	Junctions	(AJs)	is	also	of	a	great	interest	in	the	context	of	the	
BBB.	Recent	studies	point	at	VE-cadherin	(a	main	component	of	AJs)	as	a	possible	metalloproteinase	
target.	Microvascular	ECs	isolated	from	lungs	of	TIMP3	knockout	mice	showed	a	reduction	in	barrier	
ability	associated	with	a	disrupted	expression	of	membrane	VE-cadherin.	Both	barrier	function	and	
VE-cadherin	expression	were	rescued	in	the	presence	of	a	broad-spectrum	metalloproteinase	
inhibitor	(Arpino	et	al.,	2016).	It	is	important	to	consider	that	TIMP3	not	only	inhibits	MMPs,	but	also	
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several	members	of	the	ADAM	family,	including	ADAM10.	Interestingly,	Reyat	and	colleagues	
described	a	significant	increase	in	VE-cadherin	surface	expression	in	ADAM10	siRNA	knockdown	cells	
(Reyat	et	al.,	2017).	Thus,	ADAM10-mediated	VE-cadherin	cleavage	could	have	a	direct	impact	on	
BBB	stability,	although	it	is	important	to	consider	that	other	metalloproteinases	could	also	be	
involved	in	this	degradation.	In	order	to	clarify	these	observations	further	studies	are	needed	in	the	
context	of	the	BBB.	Junctional	Adhesion	Molecule	A	(JAM-A)	is	also	shed	by	ADAM17	in	cultured	
endothelial	cells	treated	with	pro-inflammatory	cytokines	(Koenen	et	al.,	2009)	and	LPS-induced	
JAM-A	cleavage	was	reduced	after	ADAM17	silencing	in	human	lung	microvascular	endothelial	cells	
(Dreymueller	et	al.,	2012b).	Interestingly,	studies	in	human	brain	microvascular	ECs	exposed	to	HIV-
infected	monocytes	revealed	that	JAM-A	shedding	was	not	exclusive	to	ADAM17,	since	normal	levels	
of	JAM-A	were	restored	after	treatment	with	an	MMP9	specific	inhibitor	(Huang	et	al.,	2009).		
Interestingly,	a	crosstalk	between	AJs	and	TJs	has	been	suggested	in	the	literature	(Tietz	and	
Engelhardt,	2015).	One	of	the	key	elements	of	this	junctional	crosstalk	is	VE-cadherin,	which	
modulates	TJ	stability	through	regulation	of	claudin-5	transcription	(Taddei	et	al.,	2008).		
Despite	the	lack	of	a	complete	characterization	of	the	claudin-5	promoter,	bioinformatic	analysis	has	
predicted	paired	binding	regions	for	Forkhead	box	protein	O1	(FoxO1)	and	β-catenin	suggesting	an	
interaction	between	these	two	transcription	factors	(Taddei	et	al.,	2008).	Chromatin	
immunoprecipitation	(ChIP)	together	with	luciferase	assays	showed	that	a	direct	interaction	
between	β-catenin	and	FoxO1	is	needed	to	stabilise	FoxO1’s	binding	to	the	claudin-5	promoter	and	
enhance	its	repressor	activity	(Taddei	et	al.,	2008).	When	forming	AJs,	transmembrane	VE-cadherin	
forms	a	complex	with	and	sequesters	β-catenin	at	the	plasma	membrane,	impairing	its	nuclear	
translocation.	Due	to	this	intracellular	redistribution,	FoxO1	repressor	activity	can	no	longer	be	
enhanced	by	β-catenin	interaction,	resulting	in	increased	claudin-5	expression	and	consequent	TJ	
stabilization	(Taddei	et	al.,	2008).		
HI
ST
OL
OG
Y 
AN
D 
HI
ST
OP
AT
HO
LO
GY
 
(no
n-e
dit
ed
 m
an
us
cri
pt)
21	
	
Additionally,	FoxO1	activity	and	cellular	localization	is	determined	by	its	phosphorylation	status:	DNA	
binding	activity	is	truncated	by	phosphorylation	at	Ser256,	whereas	nuclear	exclusion	is	promoted	by	
phosphorylation	at	Thr24	(Daitoku	et	al.,	2011).	Taddei	et	al.	demonstrated	that	clustering	of	VE-
cadherin	at	the	plasma	membrane	can	lead	to	activation	of	the	PI3K/Akt	pathway	and	consequent	
phosphorylation	of	FoxO1,	which	can	no	longer	repress	claudin-5	(Taddei	et	al.,	2008).	In	vivo	and	in	
vitro	studies	with	AKt1	null	mice	or	with	Akt-depleted	human	microvascular	ECs	(HMECs)	stimulated	
with	pro-	and	anti-vascular	agents	confirm	the	effect	of	Akt	on	FoxO-dependent	claudin-5	expression	
and	endothelial	barrier	integrity	(Gao	et	al.,	2016).	Complementary	to	these	studies,	mice	expressing	
a	truncated	form	of	VE-cadherin	lacking	the	β-catenin-binding	cytoplasmatic	tail	showed	that	a	
cadherin-catenin	complex	is	required	for	PI3K	recruitment	and	activation	of	the	PI3K/Akt	pathway	
(Carmeliet	et	al.,	1999).			
Supporting	the	hypothesis	of	VE-cadherin/β-catenin	mediated	regulation	of	claudin-5	expression,	in	
vitro	studies	with	brain	microvascular	endothelial	cells	not	only	corroborate	the	previously	discussed	
mechanisms	but	also	suggest	an	essential	role	for	non-muscle	myosin	light	chain	kinase	(nm-MLCK)	
in	the	pathway	(Beard	et	al.,	2014).	Importantly	this	study	assessed	VE-cadherin	modulation	of	TJ	
stability	under	inflammatory	conditions;	hence,	nm-MLCK	role	in	VE-cadherin/β-catenin	regulation	
of	claudin-5	expression	needs	to	be	interpreted	in	this	context,	while	other	intermediates	may	vary	
depending	on	the	extracellular	environment.	
Metalloproteinase	effects	on	AJs	should	thus	not	only	be	considered	from	the	perspective	of	a	direct	
impact	on	barrier	stability:	VE-cadherin	cleavage	will	not	only	impair	intercellular	contact	formation	
but	will	also	release	membrane-bound	β-catenin,	now	free	to	modulate	TJ	stability	through	claudin-5	
transcription.	Thus,	AJ-TJ	crosstalk	mechanisms	should	be	explored	further	in	future	BBB	studies.	
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Metzincins	as	indirect	promoters	of	BBB	integrity	
	
It	is	important	to	consider	the	possibility	that	metzincins	may	play	a	key	role	in	limiting	leukocyte	
recruitment	(one	of	the	first	steps	of	neuroinflammation)	at	the	BBB.	MMP2	(together	with	MMP13	
and	14),	can	terminate	the	inflammatory	response	through	the	cleavage	of	Macrophage	
chemoattractant	protein	3	(MCP-3)	(McQuibban	et	al.,	2000).	Full-length	MCP-3	promotes	the	
recruitment	of	active	monocytes	and	leukocytes,	but	once	cleaved	it	can	antagonize	chemokine	
receptors	attenuating	the	inflammatory	response	(McQuibban	et	al.,	2000).	MMP2	may	play	dual	
roles	during	inflammation	since	studies	in	MMP2-/-	mice	showed	earlier	onset	and	more	severe	EAE	
due	to	a	compensatory	increase	in	MMP9	(Esparza	et	al.,	2004).	In	contrast	to	this	data,	Agrawal	et	
al.	did	not	report	any	variation	in	EAE	course	or	severity	in	their	MMP2-/-	mice	when	compared	to	
wild	type	littermates,	since	EAE	resistance	was	exclusively	observed	in	MMP2	/MMP9	double	
knockout	mice	(Agrawal	et	al.,	2006).	Additionally,	fractalkine	(a	pro-inflammatory	chemokine)	can	
be	cleaved	by	MMP2	into	a	soluble	antagonist	(Dean	and	Overall,	2007).		Further	studies	will	be	
needed	to	define	the	exact	role	of	MMP2	during	the	inflammatory	response	in	the	biology	of	the	
BBB.		
MMPs	often	interface	closely	with	the	serine	proteinase	plasminogen	activator	family.	Tissue	
Plasminogen	Activator	(tPA)	has	been	shown	to	induce	BBB	disruption	by	promoting	MMP9	(Wang	
et	al.,	2003)	and	NFκβ	activation	(Cheng	et	al.,	2006).	Protease-activated	receptor	1	(PAR-1)	is	an	
intermediate	in	the	tPA/NFκβ/MMP9	pathway	(Cheng	et	al.,	2006)	that	can	be	cleaved	and	
consequently	activated	by	MMP1	(Boire	et	al.,	2005).	Although	the	impact	of	PAR-1’s	MMP1-
mediated	activation	on	the	NFκβ/MMP9	axis	has	not	yet	been	elucidated,	several	studies	have	
described	MMP1-	mediated	shedding	of	PAR-1	in	endothelial	cells	(Goerge	et	al.,	2006;	Blackburn	
and	Brinckerhoff,	2008;	Tressel	et	al.,	2011;	Nugent	et	al.,	2016).	However,	the	impact	of	this	
pathway	in	the	context	of	the	BBB	and	inflammation	remains	to	be	fully	studied.		
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von	Willebrand	factor	(VWF)	is	a	multimeric	glycoprotein	with	an	essential	role	in	thrombus	
formation	and	the	only	known	substrate	for	ADAMTS-13.	Although	the	underlying	mechanisms	are	
not	fully	understood,	in	vivo	studies	in	a	murine	stroke	model	have	revealed	that	tPA	can	increase	
VWF	plasma	levels	leading	to	BBB	disruption.	ADAMTS-13	may	mitigate	this	pathway	though	VWF	
degradation	(Wang	et	al.,	2013).	Interestingly,	studies	in	VWF-null	mice	reveal	that,	unchallenged,	
these	mice	do	not	have	a	BBB	phenotype	but	are	far	more	susceptible	to	hypoxia/reperfusion	insult.	
Although	the	status	of	ADAMTS13	in	VWF-null	mice	was	not	studied,	an	increase	in	claudin-5	levels	
was	noted	(Suidan	et	al.,	2013).	Alternatively,	tPA	can	also	induce	BBB	disruption	by	upregulating	the	
VEGF/MMP9	pathway	(Kanazawa	et	al.,	2011).	In	this	scenario,	ADAMTS13	might	protect	BBB	
stability	by	abrogating	the	VEGF	pathway	in	a	dose-dependent	manner,	though	the	molecular	
mechanisms	are	yet	unknown,	co-immunoprecipitation	experiments	point	to	a	direct	
ADAMTS13/VEGF	interaction	(Lee	et	al.,	2012).	However,	it	is	possible	ADAMTS13	also	has	
detrimental	effect	on	BBB	integrity	by	antagonising	the	positive	effect	of	VEGF	on	angiogenesis,	
opposite	to	the	effect	of	MMP9	(Bergers	et	al.,	2000).		
	
Conclusions	and	future	directions	
	
It	is	clear	that	the	BBB	plays	a	pivotal	role	in	a	wide	range	of	acute	and	chronic	inflammatory	
neurological	disorders,	including	multiple	sclerosis	and	stroke.	The	importance	and	complexity	of	
metzincin	roles	in	BBB	integrity	is	gradually	being	elucidated	and	becoming	a	more	widespread	field	
of	study.	However,	it	seems	that	metzincin	effects	on	BBB	stability	could	be	the	outcome	of	a	
complex	network	of	intracellular	mechanisms.	In	order	to	start	untangling	this	highly	intricate	
network	in	human	cells,	new	models	may	be	beneficial.	Further	refinement	of	human	BBB	models	in	
which	interactions	between	different	pathways	can	be	dissected	is	needed.	A	good	example	of	this	is	
the	novel	BBB	in	vitro	model	generated	by	Yamamizu	et	al.	(Yamamizu	et	al.,	2017)	in	which	human	
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induced	pluripotent	stem	cells	(hiPSC)	were	used	to	generate	a	co-culture	of	the	4	different	cell	
populations	integrating	the	BBB	(ECs,	pericytes,	astrocytes	and	neurons)	(Yamamizu	et	al.,	2017).		
Hence,	a	better	understanding	of	the	interplay	between	networks	and	signalling	pathways	
underlying	BBB	maintenance	could	offer	new	insights	on	BBB	pathological	dysregulation,	as	well	as	
help	to	identify	novel	therapeutic	targets	in	a	wide	range	of	neurological	disorders.		
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FIGURE	LEGENDS:	
Figure	1:	Schematic	representation	of	the	architecture	of	the	blood-brain	barrier	(BBB).	
Endothelial	Cells	(ECs)	forming	the	capillaries	establish	intercellular	contacts	known	as	tight	
junctions.	ECs	and	pericytes	are	surrounded	by	a	basement	membrane,	which	in	turn	is	also	
wrapped	by	astrocyte	foot	processes.	Astrocytes	play	a	major	role	in	BBB	maintenance	
through	the	secretion	of	several	factors	including	Shh	(not	shown).		
Figure	2:	Schematic	representation	of	Metzincin	structural	domains.	Metalloproteinases	
exhibit	a	high	structural	homology	with	a	catalytic	domain	followed	by	a	highly	conserved	
methionine	residue;	a	linker	or	hinge	peptide;	and	a	hemopexin	domain	with	a	calcium	
binding	site.	Differences	in	this	consensus	structure	have	been	used	to	classify	this	family	
members	in	the	above	specified	subgroups.	The	presence	of	a	signal	peptide	(SP)	directs	
their	secretion	or	transmembrane	anchorage.	These	metalloproteinases	are	activated	
proteolytically	through	cleavage	of	the	pro-domain.	Although	MMPs	are	secreted,	the	
presence	of	a	transmembrane	or	glycosyl	phosphatidylinositol	(GPI)	domain	allows	some	
members	of	this	family	to	anchor	to	the	cellular	membrane.	ADAMs	have	a	disintegrin-like	
domain	involved	in	cell	adhesion	together	with	a	cysteine-rich	region	and	Epidermal	Growth	
Factor	(EGF-)	like	repeats.	Structurally	similar	to	ADAMs,	ADAMTS	also	contain	a	disintegrin-
like	and	cysteine-rich	regions	(separated	by	a	thrombospondin	motive)	but	lack	a	
transmembrane	domain	and	are	thus	secreted.	
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Figure	3:	Some	of	the	possible	intracellular	mechanisms	underlying	BBB	stability.	Under	
inflammatory	conditions	cytokines	are	released	to	the	extracellular	environment.	
Endothelial	Cells	(ECs)	forming	the	Blood-Brain	Barrier	(BBB)	respond	to	these	released	
factors	through	transmembrane	receptors	(such	as	TNFR	or	ILR)	and	trigger	a	cascade	of	
intracellular	events	in	which	the	PI3K/Akt	pathway	may	function	as	a	key	node.	Cytoskeletal	
changes	triggered	by	myosin	phosphorylation	together	with	Z0-1	phosphorylation	status,	
both	potential	Akt	substrates,	seem	to	determine	Z0-1	intracellular	location	and	consequent	
TJ	formation.	Additionally,	Akt-mediated	phosphorylation	may	be	responsible	for	the	
activation	of	transcription	factors	such	as	CREB	(which	can	trigger	ZO-1	transcription),	NFκβ	
(depicted	p50/p65	and	whose	inhibitor	degradation	IkB	can	be	also	modulated	by	Akt)	
FoXO1	(in	the	absence	of	VE-cadherin,	β-catenin	is	no	longer	sequestered	in	the	membrane	
and	can	interact	with	FoXO1,	inhibiting	claudin-5	transcriptio ).	NFκβ	modulates	gene	
transcription	of	several	genes,	some	of	them	implicated	in	BBB	maintenance:	represses	TJ	
proteins	expression	while	enhancing	the	transcription	of	metzincins	such	as	MMP9,	-14,	
ADAM10	and	-17.	Interestingly,	(M)MPs	have	not	only	been	described	to	directly	cleave	TJ	
proteins	and	basement	membrane	components	but	also	cleave/activate	notch,	which	in	
turn	may	further	enhance	Akt-mediated	effects	through	inhibition	of	PTEN,	a	repressor	of	
the	PI3K/Akt	pathway.	After	Notch	cleavage,	Notch	intracellular	domain	(NICD)	is	free	to	
translocate	into	the	nucleus,	where	it	can	regulate	gene	transcription	and	impact	BBB	stability.	
Additionally,	ADAM15	can	also	impact	on	barrier	stability	not	only	through	cleavage	but	also	
by	promoting	VE-cadherin	phosphorylation	and	consequent	AJ	disassembly	through	
intracellular	signalling	cascade	triggered	with	its	cytoplasmic	tail	(not	depicted).	Interactions	
validated	in	the	BBB	are	represented	by	solid	lines,	while	dotted	lines	refer	to	connections	
described	in	a	different	cellular	context.
HI
ST
OL
OG
Y 
AN
D 
HI
ST
OP
AT
HO
LO
GY
 
(no
n-e
dit
ed
 m
an
us
cri
pt)
47	
	
	
Table	1.	—	Key	findings	regarding	metalloproteinases	effects	in	BBB	integrity	and	BBB	related	disease	
	 OBSERVATION	 STUDIED	IN	 REFERENCES	
MMP1	 Cleaves	claudins	and	occludins	but	not	Z0-1	proteins	 Co-culture	 of	 mBMEC	 with	human	breast	cancer	cells	 Wu	et	al.,	2015	
MMP2	
Required	by	monocytes,	dendritic	cells	and	activated	T	cells	to	induce	BBB	breakdown	 EAE	 Graesser	et	al.,	2000	
Resistance	to	EAE	in	MMP-2	and	MMP-9	in	double	knockout	mice		 EAE	 Agrawal	et	al.,	2006	
Positive	 feedback	mechanism:	 cytokines	 produced	 by	 leukocytes	 induce	MMP-9	 and	 -2,	
which	in	turn	can	promote	further	infiltration	of	immune	cells	 EAE	 Agrawal	et	al.,	2006	
Cleaves	claudin-5		 Cerebral	 artery	 occlusion	 and	reperfusion	in	rats	 J.	Song	et	al.,	2015	
Increase	susceptibility	to	EAE	in	MMP2-/-	mouse	due	to	a	compensatory	increase	in	MMP9	
levels	 EAE		 Yang	et	al.,	2007	
MMP3	
LPS	 intracerebral	 injection	 showed	 reduced	 BBB	 opening	 and	 neutrophil	 infiltration	 in	
MMP3-/-	mouse	 Knockout	mouse	 Esparza	et	al.,	2004	
Increased	expression	during	brain	ischemic	insult	 Ischemic	rat	brain		 Gurney	et	al.,	2006	
mRNA	levels	elevated	during	Relapsing	Remitting	Multiple	Sclerosis	 MS	patients	 Rosenberg	et	al.,	2001	
Increased	transcriptional	up-regulation	in	a	murine	virus	induced	model	of	Multiple	Sclerosis	 Murine	MS	model	 Reviewed	in	Larochelle	et	al.,	2011	
MMP7	
Increased	in	lesions	from	post-mortem	Multiple	Sclerosis	brains	 Post-mortem	brain		 Hansmann	et	al.,	2012	
mRNA	levels	elevated	during	Relapsing	Remitting	Multiple	Sclerosis	 MS	patients	 Lindberg	et	al.,	2001	
MMP8	
Serum	levels	increased	in	Multiple	Sclerosis	patients	 MS	patients	 Reviewed	in	Larochelle	et	al.,	2011	
Up-regulated	expression	levels	in	the	CNS	of	a	mouse	model	of	Multiple	Sclerosis	(EAE)	 EAE	 Reviewed	in	Larochelle	et	al.,	2011	
MMP9	
Required	by	monocytes,	dendritic	cells	and	activated	T	cells	to	induce	BBB	breakdown	 EAE	 Toft-Hansen	et	al.,	2004	
Resistance	to	EAE	in	MMP-2	and	MMP-9	in	double	knockout	mice		 EAE	 Agrawal	et	al.,	2006	
Positive	 feedback	mechanism:	 cytokines	 produced	 by	 leukocytes	 induce	MMP-9	 and	 -2,	
which	in	turn	can	promote	further	infiltration	of	immune	cells	 EAE	 Graesser	et	al.,	2000	
Higher	levels	in	MS	patients	and	associated	with	relapse	
High	serum	levels	correlated	with	BBB	disruption	in	MS	patients	 MS	patients	 Agrawal	et	al.,	2006	
Gene	knockout	is	associated	with	a	reduction	in	infarction	and	attenuation	of	BBB	opening	
after	focal	cerebral	ischemia	 Transient	focal	ischemia	in	mice	 Song	et	al.,	2015	
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Cleavage	of	Z0-1,	occludin	and	claudin-5		 Cerebral	hypoxia	mice	Brain	artery	occlusion	rats	 Lee	et	al.,	1999	
Reduced	susceptibility	to	EAE,	BBB	damage	and	infarcts	susceptibility	in	MMP9-/-	mouse	 Knockout	mouse	 Waubant	et	al.,	1999	
Polymorphisms	 in	 its	 promoter	 have	 been	 linked	 to	 increased	 susceptibility	 to	Multiple	
Sclerosis	 MS	patients	 Asahi	et	al.,	2001	
MMP10	 Up-regulated	expression	levels	in	the	CNS	of	a	mouse	model	of	Multiple	Sclerosis	(EAE)	 EAE	 Bauer	et	al.,	2010	
MMP12	
Up-regulated	expression	levels	in	the	CNS	of	a	mouse	model	of	Multiple	Sclerosis	(EAE)	 EAE	 Yang	et	al.,	2007	
Increased	susceptibility	to	EAE	in	MMP12-/-	mouse	 EAE	 Asahi	et	al.,	2001	
MMP13	 Can	enhance	BBB	permeability	through	Z0-1	fragmentation	 Primary	 rat	 astrocytes	 and	ARBECs	co-culture	 Dubois	et	al.,	1999	
MT-MMPs	
Cleavage	of		BBB	basement	membrane	components	such	as	laminin	and	collagen	IV	 In	vitro	studies	 Fiotti	et	al.,	2004	
Serum	levels	(MT-MMP1)	can	be	elevated	in	Multiple	Sclerosis	patients	 MS	patients	serum	 Toft-Hansen	et	al.,	2004	
TIMP1	 Low	serum	levels	correlated	with	BBB	disruption	in	Multiple	Sclerosis	(MS)	patients	 MS	patients	serum	 Toft-Hansen	et	al.,	2004	
ADAM10	 Promote	BBB	leakage	through	the	shedding	of	adhesion	molecules	 HUVECs	 Weaver	et	al.,	2005	
ADAM15	 ADAM15	 depletion	 can	 decrease	 endothelial	 permeability.	 This	 can	 be	 reversed	 by	 its	overexpression	 HUVECs	 Lu	et	al.,	2009	
ADAM17	 Promote	BBB	leakage	through	the	shedding	of	adhesion	molecules	Expressed	in	blood	vessels	of	MS	lesions	
HUVECs	
MS	patients	 Reviewed	in	Itoh,	2015	
ADAMTS13	 Capable	of	blocking	tPA	induced	BBB	disruption	after	cerebral	ischemia	in	mice	 Ischemia	mouse	model	 Reviewed	in	Larochelle	et	al.,	2011	
ADAMTS14	 Associated	to	Multiple	Sclerosis	through	genetic	linkage	 MS	patients	 Waubant	et	al.,	1999	
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